Sonoma Pharmaceuticals, Inc. - Investment Overview

Thinking about investing in Sonoma Pharmaceuticals? Before you commit your money, let’s break down what this company does and what this new stock offering means for you in plain English.

Note: This guide is for informational purposes only. Always do your own research or talk to a financial advisor before making investment decisions.

1. What does this company actually do?

Sonoma is a global healthcare company centered on its patented Microcyn® technology. This technology creates medical-grade hypochlorous acid, a substance that mimics how human white blood cells fight infection.

They use this to create FDA-cleared gels, sprays, and creams for skin, oral, and wound care. They sell these products to clinics and hospitals, and also offer over-the-counter options for acne, eye care, and animal health. With 20 years of history, the company manufactures its products in Mexico and distributes them in over 55 countries.

2. What is this new offering?

Sonoma is raising approximately $4 million by selling "units" at $1.35 each. Each unit includes:

• One share of common stock.
• One warrant: This gives you the right to buy another share for $1.35. These are exercisable immediately and expire in five years.

A note on "Pre-Funded Warrants": If you would own more than 4.99% or 9.99% of the company, you receive pre-funded warrants instead of standard stock. These cost $0.0001 per share to exercise and have no expiration date. However, they are not traded on any exchange, which makes them very difficult to sell if you need cash quickly.

3. Why are they doing this?

The company expects to net about $3.55 million after fees. They plan to use this capital for daily operations, research, and clinical trials. It is important to note that Sonoma has historically operated at a loss and has never paid a dividend to shareholders. They intend to reinvest all future earnings into growing the business rather than distributing profits.

4. What are the big risks?

Investing in a small pharmaceutical company is inherently risky. Here are the primary concerns to keep in mind:

• Survival Risk: The company’s own auditors have expressed "substantial doubt" about Sonoma’s ability to stay in business. They may not have enough cash to cover their bills over the next year without raising even more money.
• Dilution: By issuing new shares, the company is increasing the total number of shares in existence. This reduces your ownership percentage, which can lower the value of your individual shares.
• Control: Sonoma’s corporate bylaws make it difficult for shareholders to change management or force a sale, which effectively protects the current board from being replaced.
• Volatility: The company has utilized reverse stock splits in the past to maintain its listing on the Nasdaq. Investors often view these splits as a sign of financial distress, which can lead to significant swings in the stock price.

Final Tip: This offering carries significant risk. Between the auditors' concerns regarding the company's survival and the complex nature of the warrants, this is a high-stakes investment. If you are considering this, it may be wise to wait and observe how the market reacts to this news before making a move.